Drug Therapy for Early Rheumatoid Arthritis in Adults

335 Pages·2017·4.94 MB·English

Appendix A. Search Strings
PubMed: April 11, 2017 Original Searches
Results: 1785
Search Query Items
found
#1 Search "arthritis, rheumatoid"[MeSH Terms] OR "rheumatoid arthritis"[All Fields] 130439

#2 Search ("Adrenal Cortex Hormones"[MeSH] OR corticosteroid*) 312282

#3 Search (Methylprednisolone OR prednisone OR prednisolone) 106322

#4 Search (Hydroxychloroquine OR Leflunomide OR Methotrexate OR Sulfasalazine) 56751

#5 Search (Adalimumab OR “certolizumab pegol” OR etanercept OR golimumab OR infliximab 39136

OR Abatacept OR tocilizumab OR rituximab OR Tofacitinib OR Sarilumab OR Baricitinib OR
Sirukumab)
#6 Search (amjevita OR Inflectra OR Erelzi) 32

#7 Search (#2 OR #3 OR #4 OR #5 OR #6) 464392

#8 Search (#1 AND #7) 23197

#9 Search (letter[pt] OR newspaper article[pt] OR editorial[pt] OR comment[pt]) 1557410

#10 Search (#8 NOT #9) 21103

#11 Search (#8 NOT #9) Filters: English 16989

#12 Search (#8 NOT #9) Filters: Humans; English 14387

#13 Search (#8 NOT #9) Filters: Humans; English; Adult: 19+ years 9107

#14 Search "Randomized Controlled Trial"[Publication Type] OR "Single-Blind Method"[MeSH] 581377

OR "Double-Blind Method"[MeSH] OR "Random Allocation"[MeSH] OR
((randomized[title/abstract] OR randomised[title/abstract]) AND controlled[title/abstract] AND
trial[title/abstract])
#15 Search ("review"[Publication Type] AND "systematic"[tiab]) OR "systematic review"[All 201594

Fields] OR ("review literature as topic"[MeSH] AND "systematic"[tiab]) OR "meta-
analysis"[Publication Type] OR "meta-analysis as topic"[MeSH Terms] OR "meta-
analysis"[All Fields]
#16 Search ("Case-Control Studies"[MeSH] OR "Cohort Studies"[MeSH] OR "Epidemiologic 2247844

Studies"[MeSH] OR "Cross-Sectional Studies"[MeSH] OR "Organizational Case
Studies"[MeSH] OR "Cross-Over Studies"[MeSH] OR "Follow-Up Studies"[MeSH] OR
"Seroepidemiologic Studies"[MeSH] OR "Evaluation Studies"[Publication Type] OR
“observational study” OR “observational studies”)
#17 Search (#13 AND #14) 1303

#18 Search (#13 AND #15) 106

#19 Search (#13 AND #16) 2867

#20 Search (#13 AND #14) Filters: Publication date from 2010/07/01 529

#21 Search (#13 AND #15) Filters: Publication date from 2010/07/01 65

#22 Search (#13 AND #16) Filters: Publication date from 2010/07/01 1340

#23 Search (#20 OR #21 OR #22) Filters: Publication date from 2010/07/01 1785

A-1
Embase: April 11-12, 2017 Original Searches
Results: 1312
Search Query Results
#1 'rheumatoid arthritis'/exp OR 'rheumatoid arthritis' 196,665
#2 'adrenal cortex hormones' OR corticosteroid* 282,225
#3 methylprednisolone OR prednisone OR prednisolone 320,723
#4 hydroxychloroquine OR leflunomide OR methotrexate OR sulfasalazine 173,827
#5 adalimumab OR 'certolizumab pegol' OR etanercept OR golimumab OR infliximab OR 115,006
abatacept OR tocilizumab OR rituximab OR tofacitinib OR sarilumab OR Baricitinib OR
sirukumab
#6 amjevita OR inflectra OR erelzi 168
#7 #2 OR #3 OR #4 OR #5 OR #6 703,322
#8 #1 AND #7 56,311
#9 #8 AND ('editorial'/it OR 'letter'/it) 4,240
#10 #8 NOT #9 52,071
#11 #10 AND ([adult]/lim OR [aged]/lim OR [middle aged]/lim OR [very elderly]/lim OR 17,805
[young adult]/lim)
#12 #10 AND ([adult]/lim OR [aged]/lim OR [middle aged]/lim OR [very elderly]/lim OR 15,753
[young adult]/lim) AND [humans]/lim AND [english]/lim
#13 'randomized controlled trial'/exp OR 'single blind procedure'/exp OR 'double blind 540,522
procedure'/exp OR 'random allocation'/exp
#14 'systematic review'/exp OR 'systematic review (topic)'/exp OR 'meta-analysis'/exp OR 236,374
'meta analysis (topic)'/exp OR 'meta analysis'/exp
#15 'case control study'/exp OR 'cohort analysis'/exp OR 'epidemiological study' OR 'cross- 3,034,615
sectional study'/exp OR 'organizational case study' OR 'crossover procedure'/exp OR
'seroepidemiologic study' OR 'epidemiology'/exp OR 'multicenter study'/exp OR
'multicenter study (topic)'/exp OR 'evaluation research'/exp
#16 #12 AND #13 1,426
#17 #12 AND #14 139
#18 #12 AND #15 4,073
#19 #16 AND [2010-2017]/py 692
#20 #17 AND [2010-2017]/py 113
#21 #18 AND [2010-2017]/py 2,799
#22 #19 AND [medline]/lim 456
#23 #20 AND [medline]/lim 45
#24 #21 AND [medline]/lim 1,659
#25 #19 NOT #22 236
#26 #20 NOT #23 68
#27 #21 NOT #24 1,140
#28 #25 OR #26 OR #27 1,312

A-2
Cochrane Library: April 12, 2017 Original Searches
Results: 1067
ID Search Hits
#1 [mh "arthritis, rheumatoid"] or "rheumatoid arthritis" 9745
#2 [mh "Adrenal Cortex Hormones"] or corticosteroid 20270
#3 Methylprednisolone or prednisone or prednisolone 14571
#4 Hydroxychloroquine or Leflunomide or Methotrexate or Sulfasalazine 8664
#5 Adalimumab or "certolizumab pegol" or etanercept or golimumab or infliximab or Abatacept 6633
or tocilizumab or rituximab or Tofacitinib or Sarilumab or Baricitinib or Sirukumab
#6 amjevita or Inflectra or Erelzi 8
#7 #2 or #3 or #4 or #5 or #6 41459
#8 #1 and #7 4125
#9 "randomized controlled trial":pt or "randomized controlled trial as topic":pt or "single-blind 420356
method":pt or "double-blind method":pt or "random allocation":pt
#10 (review and systematic) or "systematic review" or ("review literature as topic" and systematic) 63119
or "meta-analysis"
#11 [mh "Cohort Studies"] or [mh "Epidemiologic Studies"] or [mh "Follow-up Studies"] or 148804
"prospective cohort" or [mh "prospective studies"] or (prospective* and cohort and (study or
studies))
#12 #8 and #9 Publication Year from 2010 to 2017 700
#13 #8 and #10 Publication Year from 2010 to 2017 320
#14 #8 and #11 Publication Year from 2010 to 2017 261
#15 #12 or #13 or #14 1067

A-3
International Pharmaceutical Abstracts: April 12, 2017
Original Searches
Results: 144
# Query Limiters/Expanders Last Run Via Results
S17 S14 OR S15 OR S16 Search modes - Interface - EBSCOhost Research 144
Boolean/Phrase Databases
Search Screen - Advanced Search
Database - International
Pharmaceutical Abstracts
S16 S10 AND S13 Limiters - Published Interface - EBSCOhost Research 35
Date: 20100101- Databases
20161231 Search Screen - Advanced Search
Search modes - Database - International
Boolean/Phrase Pharmaceutical Abstracts
S15 S10 AND S12 Limiters - Published Interface - EBSCOhost Research 64
Date: 20100101- Databases
20161231 Search Screen - Advanced Search
Search modes - Database - International
Boolean/Phrase Pharmaceutical Abstracts
S14 S10 AND S11 Limiters - Published Interface - EBSCOhost Research 85
Date: 20100101- Databases
20161231 Search Screen - Advanced Search
Search modes - Database - International
Boolean/Phrase Pharmaceutical Abstracts
S13 "Case-Control Studies” Limiters - Published Interface - EBSCOhost Research 1,628
OR "Cohort Studies" OR Date: 20100101- Databases
"Epidemiologic Studies" 20161231 Search Screen - Advanced Search
OR "Cross-Sectional Search modes - Database - International
Studies" OR Boolean/Phrase Pharmaceutical Abstracts
"Organizational Case
Studies" OR "Cross-Over
Studies" OR "Follow-Up
Studies" OR
"Seroepidemiologic
Studies" OR "Evaluation
Studies" OR
“observational study” OR
“observational studies”
S12 ("review" AND Limiters - Published Interface - EBSCOhost Research 3,143
"systematic") OR Date: 20100101- Databases
"systematic review" OR 20161231 Search Screen - Advanced Search
"meta-analysis” Search modes - Database - International
Boolean/Phrase Pharmaceutical Abstracts
S11 (("Randomized Controlled Limiters - Published Interface - EBSCOhost Research 4,755
Trial" OR "Single-Blind Date: 20100101- Databases
Method"OR "Double-Blind 20161231 Search Screen - Advanced Search
Method" OR "Random Search modes - Database - International
Allocation" OR Boolean/Phrase Pharmaceutical Abstracts
((randomized OR
randomised) AND
controlled AND trial))
S10 S1 AND S7 Limiters - Published Interface - EBSCOhost Research 878
Date: 20100101- Databases
20161231 Search Screen - Advanced Search
Narrow by Language: - Database - International
english Pharmaceutical Abstracts
Search modes -
Boolean/Phrase
A-4
# Query Limiters/Expanders Last Run Via Results
S9 S1 AND S7 Limiters - Published Interface - EBSCOhost Research 899
Date: 20100101- Databases
20161231 Search Screen - Advanced Search
Search modes - Database - International
Boolean/Phrase Pharmaceutical Abstracts
S8 S1 AND S7 Search modes - Interface - EBSCOhost Research 2,493
Boolean/Phrase Databases
Search Screen - Advanced Search
Database - International
Pharmaceutical Abstracts
S7 S2 OR S3 OR S4 OR S5 Search modes - Interface - EBSCOhost Research 20,004
OR S6 Boolean/Phrase Databases
Search Screen - Advanced Search
Database - International
Pharmaceutical Abstracts
S6 amjevita OR Inflectra OR Search modes - Interface - EBSCOhost Research 2
Erelzi Boolean/Phrase Databases
Search Screen - Advanced Search
Database - International
Pharmaceutical Abstracts
S5 Adalimumab OR Search modes - Interface - EBSCOhost Research 4,730
“certolizumab pegol” OR Boolean/Phrase Databases
etanercept OR golimumab Search Screen - Advanced Search
OR infliximab OR Database - International
Abatacept OR tocilizumab Pharmaceutical Abstracts
OR rituximab OR
Tofacitinib OR Sarilumab
OR Baricitinib OR
Sirukumab
S4 Hydroxychloroquine OR Search modes - Interface - EBSCOhost Research 5,371
Leflunomide OR Boolean/Phrase Databases
Methotrexate OR Search Screen - Advanced Search
Sulfasalazine Database - International
Pharmaceutical Abstracts
S3 Methylprednisolone OR Search modes - Interface - EBSCOhost Research 6,715
prednisone OR Boolean/Phrase Databases
prednisolone Search Screen - Advanced Search
Database - International
Pharmaceutical Abstracts
S2 "Adrenal Cortex Search modes - Interface - EBSCOhost Research 6,906
Hormones" OR Boolean/Phrase Databases
corticosteroid Search Screen - Advanced Search
Database - International
Pharmaceutical Abstracts
S1 "rheumatoid arthritis" Search modes - Interface - EBSCOhost Research 4,779
Boolean/Phrase Databases
Search Screen - Advanced Search
Database - International
Pharmaceutical Abstracts

A-5
ClinicalTrials.gov: April 12, 2017 Original Searches
Results: 622
Rheumatoid arthritis | "Adrenal Cortex Hormones" OR corticosteroid OR
Methylprednisolone OR prednisone OR prednisolone OR Hydroxychloroquine OR Leflunomide
OR Methotrexate OR Sulfasalazine OR Adalimumab OR “certolizumab pegol” OR etanercept
OR golimumab OR infliximab OR Abatacept OR tocilizumab OR rituximab OR Tofacitinib OR
Sarilumab OR Baricitinib OR Sirukumab OR amjevita OR Inflectra OR Erelzi | Adult, Senior |
Studies received from 07/01/2010 to 04/12/2017
World Health Organization International Clinical Trials
Registry Platform (WHO ICTRP): April 12, 2017 Original
Searches
Two searches, because of character limit:
For both:
Recruitment status: ALL
Date of registration between: July 1, 2010 and April 12, 2017

First search:
Results: 812 records for 353 trials; 353 (all) imported

Condition: Rheumatoid arthritis
Intervention: Adrenal Cortex Hormones OR corticosteroid OR Methylprednisolone OR
prednisone OR prednisolone OR Hydroxychloroquine OR Leflunomide OR Methotrexate OR
Sulfasalazine OR Adalimumab OR certolizumab pegol
Second search:
Results: 1136 records for 460 trials; 332 imported (128 duplicates)
Condition: Rheumatoid arthritis
etanercept OR golimumab OR infliximab OR Abatacept OR tocilizumab OR rituximab OR
Tofacitinib OR Sarilumab OR Baricitinib OR Sirukumab OR amjevita OR Inflectra OR Erelzi
New York Academy of Medicine Grey Literature Report: April
12, 2017 Original Searches
“rheumatoid arthritis”
Results: 5
A-6
Appendix B. Excluded Articles
Exclusion Code Reason for Exclusion
1 Ineligible pub type
2 Population includes age <18
3 ≥50% Patients with RA .2 yrs duration or non-RA diagnosis
4 Ineligible or No Drug(s)
5 Ineligible or no Comparator(s)
6 Ineligible Outcome(s)
7 Ineligible treatment duration
8 Ineligible setting
9 Ineligible study design
10 Non-English language
11 Study protocol or abstract-onlyrecord
12 Eligible except early RA up to 2 yrs
13 Excluded primary or companion, to be cited in review
14 Irretrievable
15 Duplicate
16 Placebo-controlled study used only in NWMA

1. Aalbers C, Gerlag D, Vos K, et al. Intra- 5. Abdulkader R, Dharmapalaiah C, Rose G, et
articular etanercept treatment in al. Late-onset neutropenia in patients with
inflammatory arthritis: A randomized rheumatoid arthritis after treatment with
double-blind placebo-controlled proof of rituximab. J Rheumatol. 2014
mechanism clinical trial validating TNF as a May;41(5):858-61. doi:
potential therapeutic target for local 10.3899/jrheum.130526. PMID: 24634201.
treatment. Joint Bone Spine. 2015 Exclusion Code: X3.
Oct;82(5):338-44. doi:
6. Abe T, Takeuchi T, Miyasaka N, et al. A
10.1016/j.jbspin.2015.03.002. PMID:
multicenter, double-blind, randomized,
26188879. Exclusion Code: X3.
placebo controlled trial of infliximab
2. Aaltonen K, Virkki L, Malmivaara A, et al. combined with low dose methotrexate in
Systematic review and meta-analysis of the Japanese patients with rheumatoid arthritis. J
efficacy and safety of existing TNF blocking Rheumatol. 2006 Jan;33(1):37-44. PMID:
agents in treatment of rheumatoid arthritis. 16395748. Exclusion Code: X3.
PLoS One; 2012. Exclusion Code: X9.
7. Aberumand B, Bykerk V, Schieir O, et al.
3. Aaltonen KJ, Sokka T, Mottonen T, et al. A Treatment response to conventional disease
nationwide cross-sectional overview of modifying anti-rheumatic drugs (DMARDS)
patients with rheumatoid arthritis followed and biologics in seropositive and
in outpatient specialty clinics in Finland. seronegative patients with early rheumatoid
Scand J Rheumatol. 2014;43(4):286-90. doi: arthritis: Results from catch (Canadian early
10.3109/03009742.2013.876512. PMID: arthritis cohort). Ann Rheum Dis.
24654994. Exclusion Code: X3. 2016;75:683-4. doi: 10.1136/annrheumdis-
2016-eular.4483. Exclusion Code: X2.
4. Abasolo L, Leon L, Rodriguez-Rodriguez L,
et al. Safety of disease-modifying 8. Accortt NA, Bonafede MM, Collier DH, et
antirheumatic drugs and biologic agents for al. Risk of Subsequent Infection Among
rheumatoid arthritis patients in real-life Patients Receiving Tumor Necrosis Factor
conditions. Semin Arthritis Rheum. 2015 Inhibitors and Other Disease-Modifying
Apr;44(5):506-13. doi: Antirheumatic Drugs. Arthritis Rheumatol.
10.1016/j.semarthrit.2014.11.003. PMID: 2016 Jan;68(1):67-76. doi:
25532946. Exclusion Code: X3. 10.1002/art.39416. PMID: 26359948.
Exclusion Code: X3.
B-1
9. Acurcio FA, Machado MAA, Moura CS, et 15. Alam MK, Sutradhar SR, Pandit H, et al.
al. Medication Persistence of Disease- Comparative study on methotrexate and
Modifying Antirheumatic Drugs and Anti– hydroxychloroquine in the treatment of
Tumor Necrosis Factor Agents in a Cohort rheumatoid arthritis. Mymensingh Med J.
of Patients With Rheumatoid Arthritis in 2012 Jul;21(3):391-8. PMID: 22828532.
Brazil. Arthritis Care Res. Exclusion Code: X12.
2016;68(10):1489-96. doi:
16. Alañón Pardo MM, Areas Del Águila VL,
10.1002/acr.22840. Exclusion Code: X9.
Cuadra Díaz JL, et al. Adherence to disease
10. Ai JW, Zhang S, Ruan QL, et al. The Risk modifying antirheumatic drugs in patients
of Tuberculosis in Patients with Rheumatoid with rheumatoid arthritis. European Journal
Arthritis Treated with Tumor Necrosis of Hospital Pharmacy. 2016;23:A45-A6.
Factor-alpha Antagonist: A Metaanalysis of doi: 10.1136/ejhpharm-2016-000875.104.
Both Randomized Controlled Trials and Exclusion Code: X3.
Registry/Cohort Studies. J Rheumatol. 2015
17. Alawneh KM, Ayesh MH, Khassawneh BY,
Dec;42(12):2229-37. doi:
et al. Anti-TNF therapy in Jordan: A focus
10.3899/jrheum.150057. PMID: 26472414.
on severe infections and tuberculosis.
Exclusion Code: X9.
Biologics: Targets and Therapy.
11. Ajeganova S, Andersson ML, Frostegard J, 2014;8:193-8. doi: 10.2147/BTT.S59574.
et al. Disease factors in early rheumatoid Exclusion Code: X3.
arthritis are associated with differential risks
18. Albattal BM. Tocilizumab efficacy and
for cardiovascular events and mortality
safety in rheumatoid arthritis patients after
depending on age at onset: a 10-year
inadequate response to disease-modifying
observational cohort study. J Rheumatol.
anti-rheumatic drugs or anti-tumor necrosis
2013 Dec;40(12):1958-66. doi:
factor. Ann Saudi Med. 2016;36(3):190-6.
10.3899/jrheum.130365. PMID: 23950188.
doi: 10.5144/0256-4947.2016.190.
Exclusion Code: X4.
Exclusion Code: X3.
12. Ajeganova S, Fiskesund R, de Faire U, et al.
19. Aletaha D, Bingham CO, Tanaka Y, et al.
Effect of biological therapy on levels of
Efficacy and safety of sirukumab in patients
atheroprotective antibodies against
with active rheumatoid arthritis refractory to
phosphorylcholine and apolipoproteins in
anti-TNF therapy (SIRROUND-T): a
rheumatoid arthritis - a one year study. Clin
randomised, double-blind, placebo-
Exp Rheumatol. 2011 Nov-Dec;29(6):942-
controlled, parallel-group, multinational,
50. PMID: 22153361. Exclusion Code: X3.
phase 3 study. The Lancet.
13. Ajeganova S, van Steenbergen HW, van 2017;389(10075):1206-17. doi:
Nies JA, et al. Disease-modifying 10.1016/S0140-6736(17)30401-4. Exclusion
antirheumatic drug-free sustained remission Code: X3.
in rheumatoid arthritis: an increasingly
20. Al-Kaissi E, Al-Muhtaseb N, Al-Muhtaseb
achievable outcome with subsidence of
N. The influence of adding antibiotic in
disease symptoms. Ann Rheum Dis. 2016
treatment of rheumatoid arthritis patients on
May;75(5):867-73. doi:
Streptococcus pyogenes carrier rate and on
10.1136/annrheumdis-2014-207080. PMID:
the lipids profile. International Journal of
25972519. Exclusion Code: X9.
Pharmacy and Pharmaceutical Sciences.
14. Akiyama M, Kaneko Y, Yamaoka K, et al. 2015;7(2):245-51. Exclusion Code: X4.
Association of disease activity with acute
21. Allaart C, Lems W, Huizinga T. The BeSt
exacerbation of interstitial lung disease
way of withdrawing biologic agents. Clin
during tocilizumab treatment in patients
Exp Rheumatol; 2014. p. S14-8. Exclusion
with rheumatoid arthritis: a retrospective,
Code: X1.
case-control study. Rheumatol Int. 2016
Jun;36(6):881-9. doi: 10.1007/s00296-016-
3478-3. PMID: 27072347. Exclusion Code:
X3.
B-2
22. Ally MM, Hodkinson B, Meyer PW, et al. 29. An M, Zou Z, Shen H, et al. The addition of
Circulating anti-citrullinated peptide tocilizumab to DMARD therapy for
antibodies, cytokines and genotype as rheumatoid arthritis: a meta-analysis of
biomarkers of response to disease-modifying randomized controlled trials (Structured
antirheumatic drug therapy in early abstract). Eur J Clin Pharmacol; 2010. p. 49-
rheumatoid arthritis. BMC Musculoskelet 59. Exclusion Code: X9.
Disord. 2015 May 29;16:130. doi:
30. Andersen T, Hvid M, Johansen C, et al.
10.1186/s12891-015-0587-1. PMID:
Interleukin-23 in early disease development
26021985. Exclusion Code: X5.
in rheumatoid arthritis. Scand J Rheumatol.
23. Al-Malaq HM, Al-Arfaj HF, Al-Arfaj AS. 2015;44(6):438-42. doi:
Adverse drug reactions caused by 10.3109/03009742.2015.1033007. PMID:
methotrexate in Saudi population. Saudi 26087654. Exclusion Code: X5.
Pharmaceutical Journal. 2012;20(4):301-5.
31. Andersson ML, Forslind K, Hafström I.
doi: 10.1016/j.jsps.2012.05.004. Exclusion
Comparing five year out-come in two
Code: X3.
cohorts of patients with early rheumatoid
24. Almeida C, Choy EH, Hewlett S, et al. arthritis – A BARFOT study. Open
Biologic interventions for fatigue in Rheumatol J. 2014;9(1):8-15. Exclusion
rheumatoid arthritis. Cochrane Database of Code: X6.
Systematic Reviews: John Wiley & Sons,
32. Andersson ML, Svensson B, Bergman S.
Ltd; 2016. Exclusion Code: X9.
Chronic widespread pain in patients with
25. Alonso A, Gonzalez CM, Ballina J, et al. rheumatoid arthritis and the relation between
Efficacy and safety of golimumab as add-on pain and disease activity measures over the
therapy to disease-modifying antirheumatic first 5 years. J Rheumatol. 2013
drugs in rheumatoid arthritis: results of the Dec;40(12):1977-85. doi:
GO-MORE study in Spain. Reumatol Clin. 10.3899/jrheum.130493. PMID: 24187108.
2015 May-Jun;11(3):144-50. doi: Exclusion Code: X5.
10.1016/j.reuma.2014.05.002. PMID:
33. Anecchino C, Fanizza C, Marino V, et al.
25022442. Exclusion Code: X3.
Drug outcome survey to evaluate anti-TNF
26. Alonso-Ruiz A, Pijoan JI, Ansuategui E, et treatment in rheumatoid arthritis: an Italian
al. Tumor necrosis factor alpha drugs in observational study (the DOSE study). Clin
rheumatoid arthritis: Systematic review and Exp Rheumatol. 2015 Nov-Dec;33(6):779-
metaanalysis of efficacy and safety. BMC 87. PMID: 26575614. Exclusion Code: X14.
Musculoskelet Disord; 2008. Exclusion
34. Anonymous. Comparative effectiveness of
Code: X9.
cycling of tumor necrosis factor-alpha
27. Alves JA, Fialho SC, Morato EF, et al. Liver (TNF-alpha) inhibitors versus switching to
toxicity is rare in rheumatoid arthritis non-TNF biologics in rheumatoid arthritis
patients using combination therapy with patients with inadequate response to TNF-
leflunomide and methotrexate. Rev Bras alpha inhibitor using a Bayesian approach.
Reumatol. 2011 Mar-Apr;51(2):141-4. p. 662. Exclusion Code: X9.
PMID: 21584420. Exclusion Code: X3.
35. Anonymous. Systematic Review of Tumor
28. Amano K, Matsubara T, Tanaka T, et al. Necrosis Factor Inhibitor Discontinuation
Long-term safety and efficacy of treatment Studies in Rheumatoid Arthritis. p. 1850.
with subcutaneous abatacept in Japanese Exclusion Code: X9.
patients with rheumatoid arthritis who are
36. Antonio JR, Sanmiguel J, Cagnon GV, et al.
methotrexate inadequate responders. Mod
Infliximab in patients with psoriasis and
Rheumatol. 2015 Sep;25(5):665-71. doi:
other inflammatory diseases: Evaluation of
10.3109/14397595.2015.1012786. PMID:
adverse events in the treatment of 168
25698370. Exclusion Code: X3.
patients. An Bras Dermatol. 2016;91(3):306-
10. doi: 10.1590/abd1806-4841.20164292.
Exclusion Code: X3.
B-3
37. Arroyo-Ávila M, Fred-Jiménez R, Pérez- 44. Askling J, van Vollenhoven RF, Granath F,
Ríos N, et al. Incident hypertension and et al. Cancer risk in patients with rheumatoid
associated factors in a hispanic group with arthritis treated with anti-tumor necrosis
rheumatoid arthritis. Arthritis and factor alpha therapies: does the risk change
Rheumatology. 2016;68:1855. doi: with the time since start of treatment?
10.1002/art.39977. Exclusion Code: X3. Arthritis Rheum; 2009. p. 3180-9. Exclusion
Code: X3.
38. Arshad N, Ahmad NM, Saeed MA, et al.
Adherence to methotrexate therapy in 45. Aslibekyan S, Sha J, Redden D, et al. Gene-
Rheumatoid Arthritis. Pakistan Journal of body mass index interactions are associated
Medical Sciences. 2016;32(2):413-7. doi: with methotrexate toxicity in rheumatoid
10.12669/pjms.322.9566. Exclusion Code: arthritis. Ann Rheum Dis; 2014. p. 785-6.
X3. Exclusion Code: X6.
39. Asai S, Kojima T, Oguchi T, et al. Effects of 46. Avila-Pedretti G, Tornero J, Fernández-
Concomitant Methotrexate on Large Joint Nebro A, et al. Variation at FCGR2A and
Replacement in Patients With Rheumatoid functionally related genes is associated with
Arthritis Treated With Tumor Necrosis the response to anti-TNF therapy in
Factor Inhibitors: A Multicenter rheumatoid arthritis. PLoS One.
Retrospective Cohort Study in Japan. 2015;10(4)doi:
Arthritis Care Res (Hoboken). 2015 10.1371/journal.pone.0122088. Exclusion
Oct;67(10):1363-70. doi: Code: X3.
10.1002/acr.22596. PMID: 25832554.
47. Avouac J, Koumakis E, Toth E, et al.
Exclusion Code: X3.
Increased risk of osteoporosis and fracture in
40. Askling J, Fored CM, Baecklund E, et al. women with systemic sclerosis: a
Haematopoietic malignancies in rheumatoid comparative study with rheumatoid arthritis.
arthritis: lymphoma risk and characteristics Arthritis Care Res (Hoboken). 2012
after exposure to tumour necrosis factor Dec;64(12):1871-8. doi: 10.1002/acr.21761.
antagonists. Ann Rheum Dis. 2005 PMID: 22730393. Exclusion Code: X3.
Oct;64(10):1414-20. PMID: 15843454.
48. Backhaus M, Kaufmann J, Richter C, et al.
Exclusion Code: X2.
Comparison of tocilizumab and tumour
41. Askling J, Fored CM, Brandt L, et al. Risk necrosis factor inhibitors in rheumatoid
and case characteristics of tuberculosis in arthritis: a retrospective analysis of 1603
rheumatoid arthritis associated with tumor patients managed in routine clinical practice.
necrosis factor antagonists in Sweden. Clin Rheumatol. 2015 Apr;34(4):673-81.
Arthritis Rheum. 2005 Jul;52(7):1986-92. doi: 10.1007/s10067-015-2879-0. PMID:
PMID: 15986370. Exclusion Code: X3. 25630309. Exclusion Code: X3.
42. Askling J, Fored CM, Brandt L, et al. Risks 49. Baddley JW, Winthrop KL, Chen L, et al.
of solid cancers in patients with rheumatoid Non-viral opportunistic infections in new
arthritis and after treatment with tumour users of tumour necrosis factor inhibitor
necrosis factor antagonists. Ann Rheum Dis. therapy: results of the SAfety Assessment of
2005 Oct;64(10):1421-6. PMID: 15829572. Biologic ThERapy (SABER) study. Ann
Exclusion Code: X3. Rheum Dis. 2014 Nov;73(11):1942-8. doi:
10.1136/annrheumdis-2013-203407. PMID:
43. Askling J, Smith M. Anti-TNFα therapy did
23852763. Exclusion Code: X3.
not increase short- or medium-term risk for
cancer in patients with rheumatoid arthritis. 50. Bae SC, Gun SC, Mok CC, et al. Improved
Ann Intern Med. 2010;152(10):JC5-13. health outcomes with etanercept versus
Exclusion Code: X1. usual DMARD therapy in an Asian
population with established rheumatoid
arthritis. BMC Musculoskelet Disord. 2013
Jan 08;14:13. doi: 10.1186/1471-2474-14-
13. PMID: 23294908. Exclusion Code: X3.
B-4